Language

Position：Home / News / Industry Information

Detonate Jiangbei | NADD FORUM 2021 Nucleic Acid Drug Development Forum Grand Opening

时间：2021-10-11 16:21:56 文章来源：苏州澳门威尼克斯人网站
May 7-8, 2021, under the guidance of Nanjing Jiangbei New District Management Committee, Nanjing Jiangbei New District Life and Health Industry Development Management Office, Nanjing Biomedicine Valley, Yimaike, and Biological Jingwei Co-sponsored“NADD FORUM 2021Nucleic Acid Drug Development Forum"In Jiangbei New District, NanjingYangtze River Boat Hotelhold. Leading companies, emerging companies, scientists, and investors from the field of nucleic acid drugs gathered in Jiangbei New Area to attend this industry event.



image.png


image.png

Moderator: Fei Jia, Director of Guangdong Engineering Technology Research Center for Small Nucleic Acid Drug Development


In recent years, China's emerging innovative drug companies have continued to emerge and grow rapidly, focusing on diversified strategies to deploy product pipelines, which has led to a situation of contention among China's innovative drug research and development. Coastal economically developed areas such as the Yangtze River Delta and the Greater Bay Area have unique resources for the innovative medicine industry. Industrial clusters around the incubation and growth of innovative medicine companies have become the focus of attention in China and the world.


image.png
image.png
image.png


The research and development of nucleic acid drugs has gone through a long development process. Its instability, immunogenicity, low cell uptake efficiency, and difficulty in escaping endosomes have restricted the development of nucleic acid drugs. However, in recent years, chemical modification and delivery systems have been restricted. Some key technological breakthroughs have played an important role in improving the above-mentioned problems.


image.png

Member of the Party Working Committee of Jiangbei New Area and Deputy Director of the Management Committee Chen Chanmei  addressed the conference


640.png

     “Nanjing Jiangbei New District serves asThe 13th in the country and the only one in Jiangsu ProvinceNational new-district，Is bearerThe innovation source, leading area and important industrial growth pole of the national strategic mission。In recent years, with the rapid development of the new district, the biomedical industry has ushered in the best development opportunities. As one of the important sectors of the industrial layout of the new district’s ‘two cities and one center’, ‘Gene City’The entire industry chain from new drug R&D and production, precision medicine, to high-end medical devices, and professional health management，500% of the industrial scale in 5 yearsGathering more than 1,000 upstream and downstream enterprises，500% of the industrial scale in 5 yearsThe ultra-high-speed growth of the country. existAccelerated deployment in the field of nucleic acid drugs, with companies such as Jimai Biotech, Oro Biotech, and Zhongji Zhiyao initially appearing，In the future, more related companies will accelerate their landings and gradually build a highland of innovation and transformation of biomedicine sources.”


image.png
image.png
image.png


The conference planned a two-day wonderful schedule,In-depth exchanges on the development status of global nucleic acid drugs。Academician of the Canadian Academy of Engineering, Chen Pu, founder of Natide Bio, Lu Yang, chairman of Senobio, Zhang Peizhuo, chairman of Gema Gene, Zhao Chunlin, founder of Anlong Bio, and Wan Jinqiao, vice president of Chengdu LeadingPioneer in the field of nucleic acid drugs, fromThe development status of nucleic acid drugs, delivery systems, R&D platform construction, technical difficulties to be broken through, innovative development and investment opportunitiesAnd so on from various angles for in-depth discussion, throughTheme sharing, round table dialogue, exhibition displayAnd other rich forms to interact with the on-site audience.
1

Theme sharing

image.png

Global progress in research and development of nucleic acid drug and vector delivery technology

Chen Pu, Academician of the Canadian Academy of Engineering, Founder of Natide Bio


image.png

The development status of global nucleic acid drugs

Gao Shan, Senior Deputy General Manager of Suzhou Ruibo Biological


image.png

Progress of nucleic acid drugs delivered by polypeptide nanoparticles (PNP) in tumor treatment

Lu Yang, Chairman of Suzhou Shengnuo Biotechnology Co., Ltd.


image.png

Helping pharmaceutical companies enter the field of RNA drugs-an open one-stop RNA drug R&D platform

Zhang Peizhuo, Chairman of Gemma Gene


image.png

Innovative development and investment opportunities of nucleic acid drugs

Zhao Chunlin, founder of Anlong Bio


image.png

From coding to nucleic acid drug development: rapid discovery and optimization of nucleic acid sequences and delivery formulations

Wan Jinqiao, Vice President of Chengdu Leading R&D Chemistry Center


image.png

Platform technology based on RNA activation and development of small nucleic acid drugs

Li Longcheng, Chairman of Sino-American Ruikang


image.png

Application development of anti-osteosarcoma of national class I new drug miRNA-21 antisense oligonucleotide (ADS-21)

Fei Jia, Director of Guangdong Engineering Technology Research Center for Small Nucleic Acid Drug Development


image.png

Research and development of new nucleic acid drug carriers

Yang Zhenjun, Professor, School of Pharmacy, Peking University Health Science Center


image.png

Research on Key Technologies of In vivo Delivery of Small Nucleic Acids

Chen Xi, Professor, Department of Biochemistry and Molecular Dean, School of Life Sciences, Nanjing University


image.png

Nucleic acid drug delivery strategy

Zhao Lixiang, Professor and Doctoral Supervisor, School of Basic Medicine and Biological Sciences, School of Medicine, Soochow University


image.png

Antibody-directed small RNA drugs to treat tumors and cognitive impairment

Zhang Hao, Professor of Jinan University School of Medicine, Director of the Institute of Tumor Precision Medicine and Pathology


2

Round table dialogue


image.png


Roundtable forum: The drug-readiness and indication expansion of small nucleic acid drugs

Zhang Yi, host, partner in charge of Huagai Medical Yangtze River Delta Fund

Chen Pu, Founder of Natide Biotech, Academician of Canadian Academy of Engineering

Liang Zicai, CEO of Ruibo Biotech

Zhang Peizhuo, Chairman of Gemma Gene

Lu Yang, Chairman of Suzhou Shengnuo Biotechnology Co., Ltd.

Zhang Biliang, Chairman of Ruibo Biological

Li Longcheng, Chairman of Sino-American Ruikang


*The conference will last for two days, May 7-8, interested friends can go to the site to participate, address: Nanjing Jiangbei New District Binjiang Avenue 504, Nanjing Hualuxe Yangtze River Boat. For more event agenda, please check "Read the original text".



HUALUXE Nanjing Yangtze River Boat
Location：
504 Binjiang Avenue, Pukou District, Nanjing City, Jiangsu Province





640.gif



Address：3rd Floor, Building B3, No. 88 Dongchang Road (2.5 Industrial Park), Suzhou Industrial Park

Tel：0512-66033978

Email：hlsw@healrna.com

About
About
Culture
Qualification
Teams
Research
Office environment
Nucleic Acid
History
Delivery technology
News
Company News
Industry Information
Contact
Contact
Recruitment

Copyright © 2020-2021 Healrna. All Rights Reserved. 苏ICP备16273928号-1